Category - Developments

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Labster to acquire UbiSim in virtual reality training expansion

Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...

October 14, 2021

Developments

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...

October 12, 2021

Developments

Titan Pharma, MUSC Foundation in research, option license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...

October 12, 2021

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Developments

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

Hirosaki University Hospital agreed to lease and utilize a Senhance Surgical System from Asensus Surgical (NYSE American: ASXC), which is digitizing the interface between surgeon and patient to enhance performance...

October 6, 2021

Developments

IntelGenx cleared to graduate to Toronto Stock Exchange

IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange. The company’s common stock; 8% convertible debentures, with a maturity date...

October 5, 2021

Developments

VistaGen reports new mechanism of action data for PH94B

VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...

October 5, 2021

Developments

Lanier Biotherapeutics in license pact with Alloy Therapeutics

Newly formed antibody developer Lanier Biotherapeutics entered into a license agreement with Alloy Therapeutics, a closely held drug discovery company. Under the accord, Alloy will acquire the AbeoMouse and Direct...

October 5, 2021

Developments

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Aquestive Therapeutics (NASDAQ:AQST), its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic...

September 30, 2021

Category - Developments

Subscribe